MX2020002348A - Métodos de elaboración de nanopartículas lipídicas. - Google Patents

Métodos de elaboración de nanopartículas lipídicas.

Info

Publication number
MX2020002348A
MX2020002348A MX2020002348A MX2020002348A MX2020002348A MX 2020002348 A MX2020002348 A MX 2020002348A MX 2020002348 A MX2020002348 A MX 2020002348A MX 2020002348 A MX2020002348 A MX 2020002348A MX 2020002348 A MX2020002348 A MX 2020002348A
Authority
MX
Mexico
Prior art keywords
nucleic acid
methods
lipid nanoparticles
acid lipid
making lipid
Prior art date
Application number
MX2020002348A
Other languages
English (en)
Spanish (es)
Inventor
Mike Smith
Joseph Schariter
Kimberly Hassett
Orn Almarsson
Luis Brito
Original Assignee
Modernatx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx Inc filed Critical Modernatx Inc
Publication of MX2020002348A publication Critical patent/MX2020002348A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277Preparation processes; Proliposomes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
MX2020002348A 2017-08-31 2018-08-31 Métodos de elaboración de nanopartículas lipídicas. MX2020002348A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762553085P 2017-08-31 2017-08-31
US201762553088P 2017-08-31 2017-08-31
US201762590193P 2017-11-22 2017-11-22
PCT/US2018/049251 WO2019046809A1 (en) 2017-08-31 2018-08-31 METHODS OF MANUFACTURING LIPID NANOPARTICLES

Publications (1)

Publication Number Publication Date
MX2020002348A true MX2020002348A (es) 2020-10-08

Family

ID=63684527

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002348A MX2020002348A (es) 2017-08-31 2018-08-31 Métodos de elaboración de nanopartículas lipídicas.

Country Status (8)

Country Link
US (2) US11744801B2 (cg-RX-API-DMAC7.html)
EP (1) EP3675817A1 (cg-RX-API-DMAC7.html)
JP (3) JP7275111B2 (cg-RX-API-DMAC7.html)
CN (1) CN111315359A (cg-RX-API-DMAC7.html)
AU (1) AU2018326799A1 (cg-RX-API-DMAC7.html)
CA (1) CA3073211A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020002348A (cg-RX-API-DMAC7.html)
WO (1) WO2019046809A1 (cg-RX-API-DMAC7.html)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS66380B1 (sr) 2014-04-23 2025-02-28 Modernatx Inc Vakcine nukleinske kiseline
WO2017020026A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
ES2910425T3 (es) 2015-09-17 2022-05-12 Modernatx Inc Compuestos y composiciones para la administración intracelular de agentes terapéuticos
EP4349405A3 (en) 2015-10-22 2024-06-19 ModernaTX, Inc. Respiratory virus vaccines
EP4036079B1 (en) 2015-12-22 2025-11-19 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
WO2017201342A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
CA3036831A1 (en) 2016-09-14 2018-03-22 Modernatx, Inc. High purity rna compositions and methods for preparation thereof
EP3538146A4 (en) 2016-11-11 2020-07-15 ModernaTX, Inc. INFLUENZA VACCINE
WO2018170336A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
RS63953B1 (sr) 2017-03-15 2023-02-28 Modernatx Inc Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
AU2018234814B2 (en) 2017-03-15 2022-06-30 Modernatx, Inc. Crystal forms of amino lipids
EP3607074A4 (en) 2017-04-05 2021-07-07 Modernatx, Inc. REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
WO2018232120A1 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. RNA FORMULATIONS
EP3668971B8 (en) 2017-08-18 2024-05-29 ModernaTX, Inc. Rna polymerase variants
EP3668979A4 (en) 2017-08-18 2021-06-02 Modernatx, Inc. METHOD OF HPLC ANALYSIS
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. HPLC ANALYTICAL PROCESSES
CA3073211A1 (en) * 2017-08-31 2019-03-07 Modernatx, Inc. Methods of making lipid nanoparticles
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
ES3001512T3 (en) 2018-04-29 2025-03-05 Global Life Sciences Solutions Canada Ulc Compositions for transfecting resistant cell types
EP3853202A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
EP3852732A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Peg lipids and uses thereof
CN112996854B (zh) 2018-09-19 2024-08-30 摩登纳特斯有限公司 高纯度peg脂质和其用途
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
WO2020077007A1 (en) 2018-10-09 2020-04-16 The University Of British Columbia Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto
MA55037A (fr) 2019-02-20 2021-12-29 Modernatx Inc Variants d'arn polymérase pour le coiffage co-transcriptionnel
KR20210149727A (ko) 2019-03-11 2021-12-09 모더나티엑스, 인크. 유가식(fed-batch) 시험관내 전사 공정
WO2020190750A1 (en) 2019-03-15 2020-09-24 Modernatx, Inc. Hiv rna vaccines
EP3982932A4 (en) * 2019-06-14 2023-10-25 Particella, Inc. COMPOSITIONS AND METHODS FOR BIOLOGICAL RELEASE VEHICLES
AR120080A1 (es) 2019-09-19 2022-02-02 Modernatx Inc Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos
US20240293317A1 (en) * 2020-04-20 2024-09-05 Board Of Regents, The University Of Texas System Lipid nanoparticle (lnp) delivery systems and uses thereof
CN116916896A (zh) * 2020-08-06 2023-10-20 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
US20230277457A1 (en) * 2020-08-06 2023-09-07 Modernatx, Inc. Methods of preparing lipid nanoparticles
EP4213882A4 (en) 2020-09-15 2025-02-26 Verve Therapeutics, Inc. LIPID FORMULATIONS FOR GENE EDITING
MX2023004371A (es) 2020-10-14 2023-07-26 George Mason Res Foundation Inc Lípidos ionizables, y métodos de fabricación y uso de los mismos.
US11591544B2 (en) 2020-11-25 2023-02-28 Akagera Medicines, Inc. Ionizable cationic lipids
KR20230143141A (ko) * 2021-01-06 2023-10-11 온코루스, 인크. 캡슐화된 rna 폴리뉴클레오타이드 및 사용 방법
US12329811B2 (en) 2021-01-11 2025-06-17 Modernatx, Inc. Seasonal RNA influenza virus vaccines
JP2024508047A (ja) * 2021-02-10 2024-02-21 オンコラス, インコーポレイテッド 化合物、組成物、及びそれらの使用方法
EP4313938A1 (en) * 2021-03-24 2024-02-07 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
US20240165044A1 (en) * 2021-04-22 2024-05-23 Inventage Lab Inc. Lipid nanoparticle preparation method and preparation apparatus therefor
WO2022232585A1 (en) * 2021-04-29 2022-11-03 Modernatx, Inc. Lyophilization methods for preparing lipid formulated therapeutics
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
CN115745942B (zh) * 2021-09-03 2025-06-10 广州谷森制药有限公司 阳离子脂质化合物
CN115772089B (zh) * 2021-09-07 2025-06-10 广州谷森制药有限公司 阳离子脂质化合物
CN113908292B (zh) * 2021-10-13 2022-08-16 南京吉迈生物技术有限公司 靶向物介导的核酸纳米制剂及其制备方法
CN113941011A (zh) * 2021-10-15 2022-01-18 浙江汇科泽华生物技术有限公司 一种含可离子化阳离子脂质的纳米脂质体颗粒及制备方法
CN114163345B (zh) * 2021-12-15 2022-07-26 武汉滨会生物科技股份有限公司 一种可离子化脂质化合物及核酸体外细胞转染试剂
CN114191561B (zh) * 2021-12-15 2022-08-02 武汉滨会生物科技股份有限公司 一种可离子化脂质化合物在核酸药物递送系统中的应用
CN116332830A (zh) * 2021-12-23 2023-06-27 苏州艾博生物科技有限公司 脂质化合物和脂质纳米颗粒组合物
CN114656422B (zh) * 2022-04-22 2023-05-23 重庆理工大学 一种新型氮杂冠醚化合物及其阳离子脂质体、制备方法与应用
CN116969851A (zh) 2022-04-29 2023-10-31 北京剂泰医药科技有限公司 可电离脂质化合物
CN117243922A (zh) * 2022-04-29 2023-12-19 北京剂泰医药科技有限公司 脂质纳米颗粒
KR20250017232A (ko) 2022-05-23 2025-02-04 로직바이오 테라퓨틱스, 인크. 유전자 요법 조성물 및 이의 사용 방법
WO2023230587A2 (en) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
EP4565209A1 (en) * 2022-08-04 2025-06-11 Sanofi Pasteur Inc. Quantitative assessment of rna encapsulation
CN115634293A (zh) * 2022-09-27 2023-01-24 石河子大学 一种靶向递送抗肿瘤药物的纳米载体的制备方法和应用
WO2024085149A1 (ja) * 2022-10-18 2024-04-25 第一三共株式会社 テイラー反応装置及びカプセル粒子の製造方法
CN116178193B (zh) 2023-01-05 2023-07-28 北京悦康科创医药科技股份有限公司 高效低毒且稳定性表达的阳离子脂质化合物及其组合物
CN116396178A (zh) * 2023-01-05 2023-07-07 北京悦康科创医药科技股份有限公司 用于递送核酸的可电离阳离子脂质化合物和组合物及用途
CN116199646B (zh) * 2023-03-07 2024-01-26 山东大学 一种基于Tris的可电离脂质及其制备方法与应用
WO2025045767A1 (en) * 2023-08-25 2025-03-06 Ethris Gmbh Stabilized lipid and lipidoid nanoparticle formulations with specific surfactant properties for enhanced pharmaceutical applications
US12491262B2 (en) 2023-10-31 2025-12-09 Tiba Biotech Llc Gene delivery agents
CN117229160B (zh) * 2023-11-13 2024-03-08 北京悦康科创医药科技股份有限公司 三酯类阳离子脂质化合物、包含其的组合物及用途
WO2025133115A1 (en) 2023-12-21 2025-06-26 Ose Immunotherapeutics Lipid-based nanoparticles comprising il-35
WO2025217298A1 (en) * 2024-04-10 2025-10-16 Georgia Tech Research Corporation Novel lipids containing diketopiperazine core, lipid nanoparticle containing thereof, and methods of using thereof
CN119174826A (zh) * 2024-08-09 2024-12-24 中日友好医院(中日友好临床医学研究所) 提高脂质纳米颗粒递送效率的方法、制备纳米载体及应用
CN120305220A (zh) * 2025-06-05 2025-07-15 郑州大学第一附属医院 一种脾脏靶向脂质纳米颗粒及其应用

Family Cites Families (573)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US5171568A (en) 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US4857319A (en) 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4946683A (en) 1987-11-18 1990-08-07 Vestar, Inc. Multiple step entrapment/loading procedure for preparing lipophilic drug-containing liposomes
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5049392A (en) 1989-01-18 1991-09-17 The Liposome Company, Inc. Osmotically dependent vesicles
DK0737750T3 (da) 1989-03-21 2003-09-01 Vical Inc Ekspression af exogene polynucleotidsekvenser i vertebrater
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
FR2676072B1 (fr) 1991-05-03 1994-11-18 Transgene Sa Vecteur de delivrance d'arn.
AU2143992A (en) 1991-08-16 1993-03-16 Vical, Inc. Composition and method for treating cystic fibrosis
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5256555A (en) 1991-12-20 1993-10-26 Ambion, Inc. Compositions and methods for increasing the yields of in vitro RNA transcription and other polynucleotide synthetic reactions
WO1993014778A1 (en) 1992-01-23 1993-08-05 Vical, Inc. Ex vivo gene transfer
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5807718A (en) 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5981501A (en) * 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US20050287540A1 (en) 1995-09-27 2005-12-29 Murphy Brian R Production of attenuated negative stranded RNA virus vaccines from cloned nucleotide sequences
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
WO1997030064A1 (en) 1996-02-16 1997-08-21 Stichting Rega Vzw Hexitol containing oligonucleotides and their use in antisense strategies
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
JP2002508299A (ja) 1997-09-19 2002-03-19 セクイター, インク. センスmRNA治療
JP2001520889A (ja) 1997-10-24 2001-11-06 バレンティス,インコーポレイティド ポリヌクレオチドトランスフェクション複合体を調製する方法
CA2309535A1 (en) 1997-11-12 1999-05-20 Brigham And Women's Hospital, Inc. The translation enhancer element of the human amyloid precursor protein gene
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6432925B1 (en) 1998-04-16 2002-08-13 John Wayne Cancer Institute RNA cancer vaccine and methods for its use
AU769357B2 (en) 1999-07-15 2004-01-22 University Of British Columbia, The Methods for preparation of lipid-encapsulated therapeutic agents
US7094423B1 (en) 1999-07-15 2006-08-22 Inex Pharmaceuticals Corp. Methods for preparation of lipid-encapsulated therapeutic agents
AU7725500A (en) 1999-09-30 2001-04-30 National Jewish Medical And Research Center Method for inhibition of pathogenic microorganisms
US6831072B2 (en) 1999-10-29 2004-12-14 Cygene, Inc. Compositions and methods of synthesis and use of novel nucleic acid structures
US7468275B2 (en) 2000-01-28 2008-12-23 The Scripps Research Institute Synthetic internal ribosome entry sites and methods of identifying same
AU3117101A (en) 2000-01-28 2001-08-07 Scripps Research Inst Synthetic internal ribosome entry sites and methods of identifying same
US6696038B1 (en) 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
US20040142474A1 (en) 2000-09-14 2004-07-22 Expression Genetics, Inc. Novel cationic lipopolymer as a biocompatible gene delivery agent
WO2002044196A1 (en) 2000-11-28 2002-06-06 University Of Massachusetts Methods and reagents for introducing a sulfhydryl group into the 5'-terminus of rna
DE10109897A1 (de) 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser
MXPA03010893A (es) 2001-05-30 2004-10-28 Univ Leland Stanford Junior Sistema de suministro para acidos nucleicos.
EP2305699B1 (de) 2001-06-05 2014-08-13 CureVac GmbH Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Impfung gegen Schlafkrankheit, Leishmaniose und Toxoplasmose
CA2462144C (en) 2001-09-28 2016-09-20 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Micro-rna molecules
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
US20050222064A1 (en) 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
IL164354A0 (en) 2002-04-04 2005-12-18 Coley Pharm Gmbh Immunostimulatory g,u-containing oligoribonucleotides
EP1509203B1 (en) 2002-05-15 2016-04-13 California Pacific Medical Center Delivery of nucleic acid-like compounds
ES2354607T3 (es) 2002-06-28 2011-03-16 Protiva Biotherapeutics Inc. Procedimiento y aparato para producir liposomas.
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
EP1873180B1 (en) 2002-08-14 2014-05-07 Novartis AG Ophthalmic device made from a radiation-curable prepolymer
US8426194B2 (en) 2003-01-21 2013-04-23 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating VEGF expression
JP4951338B2 (ja) * 2003-07-16 2012-06-13 プロチバ バイオセラピューティクス インコーポレイティッド 脂質に封入された干渉rna
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
AU2004280143A1 (en) 2003-10-11 2005-04-21 Tekmira Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
WO2005065721A2 (en) 2003-12-30 2005-07-21 Board Of Regents, The University Of Texas System Use of an anti-inflammatory compound for the reduction of inflammation secondary to the administration of a lipid-nucleic acid complex
ES2246694B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
JP4764426B2 (ja) 2004-06-07 2011-09-07 プロチバ バイオセラピューティクス インコーポレイティッド カチオン性脂質および使用方法
EP1766035B1 (en) 2004-06-07 2011-12-07 Protiva Biotherapeutics Inc. Lipid encapsulated interfering rna
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
US8663599B1 (en) 2004-10-05 2014-03-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
WO2006044503A2 (en) 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, use of these compounds for the manufacture of a medicament for treating somatic mutation-related diseases
WO2006058088A2 (en) 2004-11-23 2006-06-01 Ptc Therapeutics, Inc. Carbazole, carboline and indole derivatives useful in the inhibition of vegf production
ES2407979T3 (es) 2004-12-10 2013-06-17 Kala Pharmaceuticals, Inc. Copolímeros de bloques de poli(éter-anhídrido) funcionalizados
DE102005023170A1 (de) 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
PL2578685T3 (pl) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
WO2007025008A2 (en) 2005-08-24 2007-03-01 The Scripps Research Institute Translation enhancer-element dependent vector systems
EP1968643A2 (en) 2005-12-16 2008-09-17 Diatos Cell penetrating peptide conjugates for delivering of nucleic acids into a cell
EP2468895B1 (en) 2006-01-05 2014-09-24 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
CN103361424A (zh) 2006-01-05 2013-10-23 俄亥俄州立大学研究基金会 胰腺内分泌和腺泡肿瘤中的微小rna表达异常
DE102006007433A1 (de) 2006-02-17 2007-08-23 Curevac Gmbh Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure
WO2007103808A2 (en) 2006-03-02 2007-09-13 The Ohio State University Microrna expression profile associated with pancreatic cancer
JP2009534309A (ja) 2006-03-31 2009-09-24 マサチューセッツ インスティテュート オブ テクノロジー 治療剤の標的化送達のためのシステム
JP2009544754A (ja) 2006-07-28 2009-12-17 アプライド バイオシステムズ, エルエルシー ジヌクレオチドmrnaキャップアナログ
AU2007280690C1 (en) 2006-07-31 2012-08-23 Curevac Gmbh Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant
EP2115138A2 (en) 2006-09-19 2009-11-11 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
CA2927045A1 (en) 2006-10-03 2008-04-10 Muthiah Manoharan Lipid containing formulations
JP2010505877A (ja) 2006-10-05 2010-02-25 ザ・ジョンズ・ホプキンス・ユニバーシティー スマートな高分子ナノ粒子を用いた低水溶性薬物用の水分散性経口、非経口および局所的製剤
DE102006051516A1 (de) 2006-10-31 2008-05-08 Curevac Gmbh (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
US8252538B2 (en) 2006-11-01 2012-08-28 The Ohio State University MicroRNA expression signature for predicting survival and metastases in hepatocellular carcinoma
SG177141A1 (en) 2006-12-06 2012-01-30 Novartis Ag Vaccines including antigen from four strains of influenza virus
CN101622350A (zh) 2006-12-08 2010-01-06 奥斯瑞根公司 作为干预治疗靶标的miR-126调控基因和通路
DE102006061015A1 (de) 2006-12-22 2008-06-26 Curevac Gmbh Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
CN101616688B (zh) 2006-12-28 2013-12-11 宾夕法尼亚大学理事会 单纯疱疹病毒联合亚单位疫苗及其使用方法
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
GB0700914D0 (en) 2007-01-18 2007-02-28 Animal Health Inst Polynucleotides and uses thereof
CA2689042A1 (en) 2007-02-16 2008-08-28 Merck & Co., Inc. Compositions and methods for potentiated activity of biologicaly active molecules
WO2008127688A1 (en) 2007-04-13 2008-10-23 Hart Communication Foundation Synchronizing timeslots in a wireless communication protocol
SI2494993T1 (sl) 2007-05-04 2019-01-31 Marina Biotech, Inc. Aminokislinski lipidi in njihove uporabe
WO2008147974A1 (en) 2007-05-23 2008-12-04 University Of South Florida Micro-rnas modulating immunity and inflammation
US20090099034A1 (en) 2007-06-07 2009-04-16 Wisconsin Alumni Research Foundation Reagents and Methods for miRNA Expression Analysis and Identification of Cancer Biomarkers
US20090042825A1 (en) 2007-08-06 2009-02-12 Majed Matar Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer
US9144546B2 (en) 2007-08-06 2015-09-29 Clsn Laboratories, Inc. Nucleic acid-lipopolymer compositions
CN101835903A (zh) 2007-08-23 2010-09-15 诺瓦提斯公司 检测寡核苷酸的方法
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
EA023175B1 (ru) 2007-09-28 2016-05-31 Бинд Терапьютикс, Инк. Таргетирование раковых клеток с использованием наночастиц
EP2394657A1 (en) 2007-10-12 2011-12-14 Massachusetts Institute Of Technology Vaccine nanotechnology
CN101918594A (zh) 2007-11-30 2010-12-15 俄亥俄州立大学研究基金会 肺癌中外周血中的微rna表达特征谱和靶向
AR069495A1 (es) 2007-11-30 2010-01-27 Glaxo Group Ltd Construcciones de union de antigenos para el tratamiento de cancer o enfermedades inflamatorias (asma, artritis o artrosis)
SG188866A1 (en) 2007-12-11 2013-04-30 Scripps Research Inst Compositions and methods related to mrna translational enhancer elements
CA2710983A1 (en) 2007-12-27 2009-10-01 The Ohio State University Research Foundation Lipid nanoparticle compositions and methods of making and using the same
US9226959B2 (en) 2008-01-31 2016-01-05 Curevac Ag Nucleic acids comprising formula (NuGlXmGnNv)a and derivatives thereof as immunostimulating agent/adjuvant
EP2260110B1 (en) 2008-02-08 2014-11-12 Asuragen, INC. miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
CN102015027A (zh) 2008-02-28 2011-04-13 俄亥俄州立大学研究基金会 与人慢性淋巴细胞性白血病(ccl)相关的微rna特征和其用途
CA2721333C (en) 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
WO2009127230A1 (en) 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
EP2112235A1 (en) 2008-04-24 2009-10-28 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Compositions and methods for microRNA expression profiling of nasopharyngeal carcinoma
WO2009131704A2 (en) 2008-04-25 2009-10-29 Northwestern University Nanostructures suitable for sequestering cholesterol and other molecules
US8697098B2 (en) 2011-02-25 2014-04-15 South Dakota State University Polymer conjugated protein micelles
WO2009140427A2 (en) 2008-05-13 2009-11-19 University Of Washington Diblock copolymers and polynucleotide complexes thereof for delivery into cells
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
HUE047004T2 (hu) 2008-06-16 2020-04-28 Pfizer Hatóanyaggal töltött polimer nanorészecskék és eljárások elõállításukra és alkalmazásukra
WO2010018563A2 (en) 2008-08-12 2010-02-18 Rosetta Genomics Ltd. Compositions and methods for the prognosis of lymphoma
WO2010033906A2 (en) 2008-09-19 2010-03-25 President And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
JP5777519B2 (ja) 2008-10-09 2015-09-09 テクミラ ファーマシューティカルズ コーポレイション 改良されたアミノ脂質および核酸の送達方法
US20100112042A1 (en) * 2008-10-16 2010-05-06 Mdrna, Inc. Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics
CA3006395C (en) 2008-11-07 2022-05-31 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
PL2355851T3 (pl) 2008-11-10 2018-08-31 Arbutus Biopharma Corporation Nowe lipidy i kompozycje do dostarczania środków terapeutycznych
WO2010057203A2 (en) 2008-11-17 2010-05-20 The Board Of Regents Of The University Of Texas System Hdl particles for delivery of nucleic acids
WO2010066384A1 (en) 2008-12-10 2010-06-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Compositions and methods for micro-rna expression profiling of cancer stem cells
US8563041B2 (en) 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
EP3243504A1 (en) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
WO2010088927A1 (en) 2009-02-09 2010-08-12 Curevac Gmbh Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds
CA2754043A1 (en) 2009-03-12 2010-09-16 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
US8460696B2 (en) 2009-03-20 2013-06-11 Egen, Inc. Polyamine derivatives
US20120095077A1 (en) 2009-03-23 2012-04-19 University Of Utah Research Foundation Methods and compositions related to modified guanine bases for controlling off-target effects in rna interference
US8883202B2 (en) 2009-05-05 2014-11-11 Tekmira Pharmaceuticals Corporation Lipid compositions
EP2427574A2 (en) 2009-05-08 2012-03-14 The Ohio State University Research Foundation Microrna expression profiling and targeting in chronic obstructive pulmonary disease (copd) lung tissue and methods of use thereof
LT2440183T (lt) 2009-06-10 2018-08-10 Arbutus Biopharma Corporation Patobulinta lipido kompozicija
US8283333B2 (en) 2009-07-01 2012-10-09 Protiva Biotherapeutics, Inc. Lipid formulations for nucleic acid delivery
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
WO2011017297A2 (en) * 2009-08-03 2011-02-10 The University Of North Carolina At Chapel Hill Biodegradable delivery system complexes for the delivery of bioactive compounds
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
CA2816925C (en) 2009-11-04 2023-01-10 The University Of British Columbia Nucleic acid-containing lipid particles and related methods
US9415113B2 (en) 2009-11-18 2016-08-16 University Of Washington Targeting monomers and polymers having targeting blocks
US20110244026A1 (en) 2009-12-01 2011-10-06 Braydon Charles Guild Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
CA3044884A1 (en) 2009-12-07 2011-06-16 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
KR102505097B1 (ko) 2009-12-07 2023-03-02 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 세포 리프로그래밍을 위한 정제된 변형 rna를 포함하는 rna 제제
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
ES2721898T3 (es) 2009-12-11 2019-08-06 Pfizer Formulaciones estables para liofilizar partículas terapéuticas
US20110144544A1 (en) 2009-12-15 2011-06-16 General Electric Company Ultrasound transducer assembly and methods of using
EP2512449B1 (en) 2009-12-18 2019-08-07 The University of British Columbia Methods and compositions for delivery of nucleic acids
AU2010334911A1 (en) 2009-12-23 2012-07-12 Novartis Ag Lipids, lipid compositions, and methods of using them
WO2011076142A1 (en) 2009-12-24 2011-06-30 Fudan University Compositions and methods for microrna expession profiling in plasma of colorectal cancer
WO2011076143A1 (en) 2009-12-24 2011-06-30 Fudan University Compositions and methods for microrna expression profiling of lung cancer
EP2341145A1 (en) 2009-12-30 2011-07-06 febit holding GmbH miRNA fingerprint in the diagnosis of diseases
WO2011094683A2 (en) 2010-01-29 2011-08-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of identifying myelodysplastic syndromes
EP2354246A1 (en) 2010-02-05 2011-08-10 febit holding GmbH miRNA in the diagnosis of ovarian cancer
WO2011113030A2 (en) 2010-03-11 2011-09-15 H.Lee Moffitt Cancer Center & Research Institute Human cancer micro-rna expression profiles predictive of chemo-response
US9149432B2 (en) 2010-03-19 2015-10-06 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
WO2011119058A2 (en) 2010-03-22 2011-09-29 Universidade De Coimbra F3-peptide targeted lipid-based nanoparticles useful for the treatment of angiogenesis-dependent diseases
WO2011120053A1 (en) 2010-03-26 2011-09-29 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
EP3391877A1 (en) 2010-04-08 2018-10-24 The Trustees of Princeton University Preparation of lipid nanoparticles
JP5794541B2 (ja) * 2010-04-21 2015-10-14 国立大学法人北海道大学 核内移行性を有する脂質膜構造体
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
US9254327B2 (en) 2010-05-10 2016-02-09 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2011141704A1 (en) 2010-05-12 2011-11-17 Protiva Biotherapeutics, Inc Novel cyclic cationic lipids and methods of use
EP2569276B1 (en) 2010-05-12 2021-02-24 Arbutus Biopharma Corporation Novel cationic lipids and methods of use thereof
EP2387999A1 (en) 2010-05-21 2011-11-23 CureVac GmbH Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof
JP2013531634A (ja) 2010-05-24 2013-08-08 メルク・シャープ・エンド・ドーム・コーポレイション オリゴヌクレオチド送達のための新規なアミノアルコールカチオン性脂質
JP5957646B2 (ja) 2010-06-04 2016-07-27 サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. オリゴヌクレオチド送達のための新規な低分子量カチオン性脂質
WO2011157294A1 (en) 2010-06-16 2011-12-22 Universita' Degli Studi Di Padova Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto
WO2011163121A1 (en) 2010-06-21 2011-12-29 Alnylam Pharmaceuticals, Inc. Multifunctional copolymers for nucleic acid delivery
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
PL2590626T3 (pl) 2010-07-06 2016-04-29 Glaxosmithkline Biologicals Sa Liposomy z lipidami o korzystnej wartości pka do dostarczania rna
SI2590676T1 (sl) 2010-07-06 2016-11-30 Glaxosmithkline Biologicals, S.A. Virionu podobni delci za dajanje za samorepliciranje RNA molekul
US20130230884A1 (en) 2010-07-16 2013-09-05 John Chaput Methods to Identify Synthetic and Natural RNA Elements that Enhance Protein Translation
CN107648604A (zh) 2010-07-30 2018-02-02 库瑞瓦格股份公司 聚合物载体运载物复合物及聚合物载体的用途
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
SI3970742T1 (sl) 2010-08-31 2022-08-31 Glaxosmithkline Biologicals S.A. Pegilirani liposomi za dostavo RNA, ki kodira imunogen
WO2012030901A1 (en) 2010-08-31 2012-03-08 Novartis Ag Small liposomes for delivery of immunogen-encoding rna
CN103384515B (zh) 2010-08-31 2017-02-15 诺华有限公司 适用于脂质体递送编码蛋白质的rna的脂质
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
US8466122B2 (en) 2010-09-17 2013-06-18 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
RU2617641C2 (ru) 2010-09-20 2017-04-25 Сирна Терапьютикс,Инк. Новые низкомолекулярные катионные липиды для доставки олигонуклеотидов
EP2621480B1 (en) 2010-09-30 2018-08-15 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
MX2013003681A (es) 2010-10-01 2013-11-20 Moderna Therapeutics Inc Ácidos nucleicos manipulados y métodos de uso de los mismos.
CN103153347A (zh) 2010-10-21 2013-06-12 默沙东公司 用于寡核苷酸递送的新型低分子量阳离子脂质
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
US10364440B2 (en) 2011-01-04 2019-07-30 Brown University Nanotubes as carriers of nucleic acids into cells
US9999673B2 (en) 2011-01-11 2018-06-19 Alnylam Pharmaceuticals, Inc. PEGylated lipids and their use for drug delivery
CN102068701B (zh) 2011-01-18 2012-11-07 沈阳药科大学 可断裂peg脂质衍生物在制剂中的应用
US10363309B2 (en) 2011-02-04 2019-07-30 Case Western Reserve University Targeted nanoparticle conjugates
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
JP6054308B2 (ja) 2011-02-15 2016-12-27 メリマック ファーマシューティカルズ, インコーポレイテッドMerrimack Pharmaceuticals, Inc. 核酸を細胞へ送達する組成物及び方法
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
CN102204920B (zh) 2011-03-18 2013-03-20 海南本创医药科技有限公司 阿司匹林钠普伐他汀钠药物组合物固体制剂
EP2688590B1 (en) 2011-03-24 2020-02-12 GlaxoSmithKline Biologicals SA Adjuvant nanoemulsions with phospholipids
PL2691443T3 (pl) 2011-03-28 2021-08-30 Massachusetts Institute Of Technology Sprzężone lipomery i ich zastosowania
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
WO2013158127A1 (en) 2012-04-16 2013-10-24 Molecular Transfer, Inc. Agents for improved delivery of nucleic acids to eukaryotic cells
EP3238709B1 (en) 2011-04-28 2020-07-01 Platform Brightworks Two, Ltd. Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
US9579283B2 (en) 2011-04-28 2017-02-28 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same
CN118078979A (zh) 2011-04-29 2024-05-28 西莱克塔生物科技公司 用于降低针对治疗性蛋白的免疫应答的致耐受性合成纳米载体
US20140113978A1 (en) 2011-05-01 2014-04-24 University Of Rochester Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof
EP2705370A2 (en) 2011-05-06 2014-03-12 Xentech Markers for cancer prognosis and therapy and methods of use
WO2012153297A1 (en) 2011-05-11 2012-11-15 Ramot At Tel-Aviv University Ltd. Targeted polymeric conjugates and uses thereof
WO2012152910A1 (en) 2011-05-12 2012-11-15 Helmut Vockner Novel pharmaceutical formulation
JP2014519493A (ja) 2011-05-12 2014-08-14 イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド ポリマー共役脂質を含むリポソームおよび関連用途
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
EP2710136A4 (en) 2011-05-17 2015-01-21 Moderna Therapeutics Inc MANIPULATED NUCLEIC ACIDS AND USE METHOD FOR NON-HUMAN SPINE
WO2012159643A1 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
AU2012262961A1 (en) 2011-06-02 2013-11-28 Novartis Ag Biomarkers for hedgehog inhibitor therapy
DK2714017T3 (en) 2011-06-02 2018-09-03 Univ California MEMBRANE-WRAPPED NANOPARTICLES AND METHOD OF USE
LT2717893T (lt) 2011-06-08 2019-08-12 Translate Bio, Inc. Lipidų nanodalelių kompozicijos ir mrnr pristatymo būdai
DK3336082T3 (da) 2011-06-08 2020-04-27 Translate Bio Inc Spaltelige lipider
KR102038300B1 (ko) 2011-06-08 2019-10-31 닛토덴코 가부시키가이샤 표적 약물 전달체 및 siRNA 활성을 증가시키는 화합물
CN102813929B (zh) 2011-06-09 2014-04-09 沈阳药科大学 低浓度peg脂质衍生物及其应用
WO2012168491A1 (en) 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
WO2012170607A2 (en) 2011-06-10 2012-12-13 Novartis Ag Use of pcsk9 antagonists
US11058762B2 (en) 2011-07-06 2021-07-13 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof
JP6059220B2 (ja) 2011-07-06 2017-01-18 ノバルティス アーゲー 核酸を含む水中油型エマルジョン
SG10201605537XA (en) 2011-07-06 2016-09-29 Novartis Ag Liposomes having useful n:p ratio for delivery of rna molecules
US11896636B2 (en) 2011-07-06 2024-02-13 Glaxosmithkline Biologicals Sa Immunogenic combination compositions and uses thereof
MX350258B (es) 2011-07-06 2017-08-31 Novartis Ag Emulsiones cationicas de aceite en agua.
US20140272998A1 (en) 2011-07-15 2014-09-18 Leo Pharma A/S Diagnostic microrna profiling in cutaneous t-cell lymphoma (ctcl)
EP2734184B1 (en) 2011-07-21 2018-03-28 Croda International Plc Branched polyether-polyamide block copolymers and methods of making and using the same
HK1199736A1 (en) 2011-08-26 2015-07-17 箭头研究公司 Poly(vinyl ester) polymers for in vivo nucleic acid delivery
US9126966B2 (en) 2011-08-31 2015-09-08 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use thereof
PT2750707T (pt) * 2011-08-31 2019-01-23 Glaxosmithkline Biologicals Sa Lipossomas peguilados para distribuição de arn que codifica imunogénio
CN103930135A (zh) 2011-08-31 2014-07-16 马林克罗特有限公司 使用h-膦酸酯的纳米颗粒peg修饰
EP2751292A4 (en) 2011-09-01 2015-05-20 Allegro Diagnostics Corp METHOD AND COMPOSITIONS FOR DETECTING CANCER BASED ON MIRNA EXPRESSION PROFILES
MX2014002486A (es) 2011-09-01 2014-12-08 Irm Llc Compuestos y composiciones como inhibidores de cinasa pdgfr.
EP3384938A1 (en) 2011-09-12 2018-10-10 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9375388B2 (en) 2011-09-23 2016-06-28 Indian Institute Of Technology, Bombay Nanoparticle based cosmetic composition
WO2013049328A1 (en) 2011-09-27 2013-04-04 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted pegylated lipids
US12371522B2 (en) 2011-10-12 2025-07-29 The Johns Hopkins University Bioreducible poly (beta-amino ester)s for siRNA delivery
EP2765997A4 (en) 2011-10-14 2015-06-24 Stc Unm POROUS NANOPARTICLE-SUPPORTED LIPID DOUBLE LAYERS (PROTOCOLS) FOR THE TARGETED RELEASE BY TRANSDERMAL RELEASE AND USE METHOD THEREFOR
DK2768958T3 (da) 2011-10-18 2019-09-16 Dicerna Pharmaceuticals Inc Kationiske aminlipider og anvendelser deraf
CA2852857A1 (en) 2011-10-20 2013-04-25 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
EP3069785A1 (en) 2011-10-25 2016-09-21 The University Of British Columbia Limit size lipid nanoparticles and related methods
US20140243240A1 (en) 2011-10-26 2014-08-28 Georgetown University microRNA EXPRESSION PROFILING OF THYROID CANCER
EP4074694A1 (en) 2011-10-27 2022-10-19 Massachusetts Institute Of Technology Amino acid-, peptide- an polypeptide-lipids, isomers, compositions, an uses thereof
EP3424564A1 (en) 2011-10-31 2019-01-09 Mallinckrodt LLC Combinational liposome compositions for cancer therapy
JP6143269B2 (ja) 2011-11-04 2017-06-07 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ 自己組織化複合超小型ペプチドポリマーヒドロゲル
SI2773326T1 (sl) 2011-11-04 2019-04-30 Nitto Denko Corporation Metoda za sterilno proizvodnjo delcev lipidno-nukleinske kisline
US9579338B2 (en) 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
US9872870B2 (en) 2011-11-04 2018-01-23 University Of Notre Dame Du Lac Multifunctional micellar nanoparticle-based drug and targeting agent system
WO2013070872A1 (en) 2011-11-08 2013-05-16 The Board Of Trustees Of The University Of Arkansas Methods and compositions for x-ray induced release from ph sensitive liposomes
WO2013082529A1 (en) 2011-12-02 2013-06-06 Yale University Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery
WO2013086373A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
DE21212055T1 (de) 2011-12-07 2022-08-04 Alnylam Pharmaceuticals, Inc. Biologisch abbaubare lipide zur freisetzung von wirkstoffen
AU2012347605B2 (en) 2011-12-07 2017-09-21 Alnylam Pharmaceuticals, Inc. Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
EP2787977A4 (en) 2011-12-09 2015-05-06 Univ California LIPOSOMAL ACTIVE INVERTING
TWI594767B (zh) 2011-12-12 2017-08-11 協和醱酵麒麟有限公司 含有陽離子性脂質之藥物傳遞系統用脂質奈米粒子
JP6182458B2 (ja) 2011-12-12 2017-08-16 協和発酵キリン株式会社 カチオン性脂質の組み合わせを含有する脂質ナノ粒子
EP2604253A1 (en) 2011-12-13 2013-06-19 Otto Glatter Water-in-oil emulsions and methods for their preparation
US20140378538A1 (en) 2011-12-14 2014-12-25 Moderma Therapeutics, Inc. Methods of responding to a biothreat
US9636414B2 (en) 2011-12-15 2017-05-02 Biontech Ag Particles comprising single stranded RNA and double stranded RNA for immunomodulation
SMT202200355T1 (it) 2011-12-16 2022-11-18 Modernatx Inc Composizioni di mrna modificato
WO2013090601A2 (en) 2011-12-16 2013-06-20 Massachusetts Institute Of Technology Compact nanoparticles for biological applications
CA2859691A1 (en) 2011-12-21 2013-06-27 Moderna Therapeutics, Inc. Methods of increasing the viability or longevity of an organ or organ explant
PL3144389T3 (pl) 2011-12-30 2018-10-31 Cellscript, Llc WYTWARZANIE I STOSOWANIE ZSYNTETYZOWANEGO IN VITRO ssRNA DO WPROWADZANIA DO SSACZYCH KOMÓREK W CELU INDUKCJI EFEKTU BIOLOGICZNEGO LUB BIOCHEMICZNEGO
WO2013103659A1 (en) 2012-01-04 2013-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus
EP2807251B1 (en) 2012-01-26 2018-01-10 Life Technologies Corporation Methods for increasing the infectivity of viruses
WO2013112780A1 (en) 2012-01-26 2013-08-01 Life Technologies Corporation Methods for increasing the infectivity of viruses
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
WO2013113325A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
EP2623121A1 (en) 2012-01-31 2013-08-07 Bayer Innovation GmbH Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
HK1205751A1 (en) 2012-02-22 2015-12-24 Cerulean Pharma Inc. Conjugates, particles, compositions, and related methods
HUE041494T2 (hu) 2012-02-24 2019-05-28 Arbutus Biopharma Corp Trialkil-kationos lipidek és alkalmazási módszereik
US10322089B2 (en) 2012-03-14 2019-06-18 The Board Of Trustees Of The Leland Stanford Junior University Nanoparticles, nanoparticle delivery methods, and systems of delivery
EP2825206A1 (en) 2012-03-16 2015-01-21 The Johns Hopkins University Controlled release formulations for the delivery of hif-1 inhibitors
AU2013231638B2 (en) 2012-03-16 2017-10-12 Merck Patent Gmbh Targeting aminoacid lipids
US10159743B2 (en) 2012-03-16 2018-12-25 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
US9717685B2 (en) 2012-03-26 2017-08-01 President And Fellows Of Harvard College Lipid-coated nucleic acid nanostructures of defined shape
SG10201607966UA (en) 2012-03-27 2016-11-29 Curevac Ag Artificial nucleic acid molecules comprising a 5'top utr
CA2866955A1 (en) 2012-03-27 2013-10-03 Curevac Gmbh Artificial nucleic acid molecules
WO2013148541A1 (en) 2012-03-27 2013-10-03 Merck Sharp & Dohme Corp. DIETHER BASED BIODEGRADABLE CATIONIC LIPIDS FOR siRNA DELIVERY
MX2019002345A (es) 2012-03-27 2022-08-24 Curevac Ag Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
ES2858523T3 (es) 2012-03-29 2021-09-30 Translate Bio Inc Nanopartículas neutras derivadas de lípidos
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
CN108949772A (zh) 2012-04-02 2018-12-07 现代泰克斯公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
EP2834260A4 (en) 2012-04-02 2016-08-10 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS
WO2013151650A1 (en) 2012-04-05 2013-10-10 University Of Florida Research Foundation, Inc. Neurophilic nanoparticles
HK1210479A1 (en) 2012-04-10 2016-04-22 The Trustees Of The University Of Pennsylvania Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
MX340992B (es) 2012-04-11 2016-08-03 Intezyne Tech Inc Copolimeros de bloque para micelas estables.
CA2869748C (en) 2012-04-12 2017-10-24 Yale University Vehicles for controlled delivery of different pharmaceutical agents
JP6232416B2 (ja) 2012-04-19 2017-11-15 サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. オリゴヌクレオチド送達のための、新規なジエステルおよびトリエステルベースの低分子量、生分解性カチオン性脂質
US9889208B2 (en) 2012-05-04 2018-02-13 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
WO2013173693A1 (en) 2012-05-18 2013-11-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nanoparticles with enhanced entry into cancer cells
MX353567B (es) 2012-05-23 2018-01-18 Univ Ohio State Composiciones de nanoparticulas de lipidos para la entrega de oligonucleotidos antisentido.
ES2719598T3 (es) 2012-05-25 2019-07-11 Curevac Ag Inmovilización reversible y/o liberación controlada de ácidos nucleicos contenidos en nanopartículas mediante revestimientos poliméricos (biodegradables)
TWI654997B (zh) 2012-06-08 2019-04-01 日商日東電工股份有限公司 用於治療劑輸送配方之脂質
US10245229B2 (en) 2012-06-08 2019-04-02 Translate Bio, Inc. Pulmonary delivery of mRNA to non-lung target cells
WO2014008334A1 (en) 2012-07-06 2014-01-09 Alnylam Pharmaceuticals, Inc. Stable non-aggregating nucleic acid lipid particle formulations
WO2014024193A1 (en) 2012-08-07 2014-02-13 Prodel Pharma Ltd. Compositions and methods for rapid transmucosal delivery of pharmaceutical ingredients
US9931418B2 (en) 2012-08-07 2018-04-03 Northeastern University Compositions for the delivery of RNA and drugs into cells
WO2014028487A1 (en) * 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
WO2014026284A1 (en) 2012-08-14 2014-02-20 Froese Aaron Internal structured self assembling liposomes
EP2885419A4 (en) 2012-08-14 2016-05-25 Moderna Therapeutics Inc ENZYMES AND POLYMERASES FOR RNA SYNTHESIS
US10231997B2 (en) 2012-08-15 2019-03-19 The University Of Chicago Exosome-based therapeutics against neurodegenerative disorders
US8703197B2 (en) 2012-09-13 2014-04-22 International Business Machines Corporation Branched polyamines for delivery of biologically active materials
KR20150056618A (ko) 2012-09-17 2015-05-26 바인드 쎄라퓨틱스, 인크. 치료 나노입자의 제조 방법
WO2014047649A1 (en) 2012-09-24 2014-03-27 The Regents Of The University Of California Methods for arranging and packing nucleic acids for unusual resistance to nucleases and targeted delivery for gene therapy
US20150246137A1 (en) 2012-09-27 2015-09-03 The University Of North Carolina At Chapel Hill Lipid coated nanoparticles containing agents having low aqueous and lipid solubilities and methods thereof
CN104812372A (zh) 2012-10-04 2015-07-29 约翰内斯堡金山大学 脂质体药物递送系统
WO2014053881A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2014053879A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2014053880A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2014053882A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
IN2015DN04147A (cg-RX-API-DMAC7.html) 2012-10-16 2015-10-16 Endocyte Inc
EP2908864B1 (en) 2012-10-22 2019-12-11 Sabag-Rfa Ltd. Phosphate compounds for delivering therapeutic agents into living cells and cells nuclei
CA2889608A1 (en) 2012-10-26 2014-05-01 Nlife Therapeutics, S.L. Compositions and methods for selective delivery of oligonucleotide molecules to cell types
US20150272900A1 (en) 2012-10-26 2015-10-01 The Johns Hopkins University Layer-By-Layer Approach to Co-Deliver DNA and siRNA via AuNPs: A Potential Platform for Modifying Release Kinetics
WO2014071072A2 (en) 2012-11-02 2014-05-08 Pungente Michael D Novel cationic carotenoid-based lipids for cellular nucleic acid uptake
CA2890333C (en) 2012-11-06 2021-03-23 Rochal Industries, Llc Delivery of biologically-active agents using volatile, hydrophobic solvents
US9669104B2 (en) 2012-11-07 2017-06-06 Council Of Scientific And Industrial Research Nanocomplex containing amphipathic peptide useful for efficient transfection of biomolecules
CN110893188A (zh) 2012-11-08 2020-03-20 克莱尔塞德生物医学股份有限公司 用于在人类受试者中治疗眼部疾病的方法和装置
US9200119B2 (en) 2012-11-09 2015-12-01 Momentive Performance Materials Inc. Silicon-containing zwitterionic linear copolymer composition
EP2916853B1 (en) 2012-11-09 2020-05-06 Velin-Pharma A/S Compositions for pulmonary delivery
KR20150083121A (ko) 2012-11-12 2015-07-16 레드우드 바이오사이언스 인코포레이티드 화합물, 및 컨쥬게이트의 제조방법
WO2014078399A1 (en) 2012-11-13 2014-05-22 Baylor College Of Medicine Multi-arm biodegradable polymers for nucleic acid delivery
EP2732825B1 (en) 2012-11-19 2015-07-01 Invivogen Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist
US20150290328A1 (en) 2012-11-20 2015-10-15 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
WO2014081299A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Activatable liposomes
EP4245744A3 (en) 2012-11-22 2024-05-01 Tagworks Pharmaceuticals B.V. Chemically cleavable group
WO2014081300A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Channel protein activatable liposomes
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
WO2014089486A1 (en) 2012-12-07 2014-06-12 Shire Human Genetic Therapies, Inc. Lipidic nanoparticles for mrna delivering
WO2014089239A1 (en) 2012-12-07 2014-06-12 Alnylam Pharmaceuticals, Inc. Improved nucleic acid lipid particle formulations
WO2014093574A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified polynucleotides for altering cell phenotype
EP2931319B1 (en) 2012-12-13 2019-08-21 ModernaTX, Inc. Modified nucleic acid molecules and uses thereof
CN104902925A (zh) 2013-01-10 2015-09-09 诺华股份有限公司 流感病毒免疫原性组合物及其应用
EP3434774A1 (en) 2013-01-17 2019-01-30 ModernaTX, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
MX385338B (es) 2013-02-22 2025-03-18 CureVac SE Combinación de vacunación e inhibición de la trayectoria pd-1.
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
KR102310921B1 (ko) 2013-03-14 2021-10-13 다이서나 파마수이티컬, 인크. 음이온성 약제를 제형화하는 방법
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
MX2015012865A (es) 2013-03-14 2016-07-21 Shire Human Genetic Therapies Metodos para purificacion de arn mensajero.
US20160032316A1 (en) 2013-03-14 2016-02-04 The Trustees Of The University Of Pennsylvania Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides
WO2014144039A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Characterization of mrna molecules
CN105283548A (zh) 2013-03-15 2016-01-27 葛兰素史密斯克莱生物公司 Rna纯化方法
US9693958B2 (en) 2013-03-15 2017-07-04 Cureport, Inc. Methods and devices for preparation of lipid nanoparticles
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10138507B2 (en) 2013-03-15 2018-11-27 Modernatx, Inc. Manufacturing methods for production of RNA transcripts
US10342760B2 (en) 2013-03-15 2019-07-09 The University Of British Columbia Lipid nanoparticles for transfection and related methods
PL4332576T3 (pl) 2013-03-15 2025-09-08 Translate Bio, Inc. Synergistyczne wzmocnienie dostarczania kwasów nukleinowych poprzez formulacje zmieszane
EP4279610A3 (en) 2013-03-15 2024-01-03 ModernaTX, Inc. Ribonucleic acid purification
US10590161B2 (en) 2013-03-15 2020-03-17 Modernatx, Inc. Ion exchange purification of mRNA
US9593139B2 (en) * 2013-04-05 2017-03-14 Massachusetts Institute Of Technology Compositions, methods, and kits comprising platinum compounds associated with a ligand comprising a targeting moiety
JP6702855B2 (ja) 2013-04-07 2020-06-03 ザ・ブロード・インスティテュート・インコーポレイテッド 個別化された新生物ワクチンの組成物及び方法
EP2994167B1 (en) 2013-05-06 2020-05-06 Alnylam Pharmaceuticals, Inc. Dosages and methods for delivering lipid formulated nucleic acid molecules
WO2014210356A1 (en) 2013-06-26 2014-12-31 Massachusetts Institute Of Technology Multi-tailed lipids and uses thereof
WO2015002667A1 (en) 2013-07-01 2015-01-08 Myq, Inc. A location regulated point-of-sale system and enhancements
TW201534578A (zh) 2013-07-08 2015-09-16 Daiichi Sankyo Co Ltd 新穎脂質
PL3019619T3 (pl) 2013-07-11 2022-01-10 Modernatx, Inc. Kompozycje zawierające syntetyczne polinkleotydy kodujące białka powiązane z crispr i syntetyczne sgrna oraz sposoby ich stosowania
CN105555757A (zh) * 2013-07-23 2016-05-04 普洛体维生物治疗公司 用于递送信使rna的组合物和方法
JP6685903B2 (ja) 2013-07-25 2020-04-22 アバター・メディカル・エルエルシー 立体構造的に安定化されたrsv融合前fタンパク質
WO2015023461A2 (en) 2013-08-06 2015-02-19 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
MX2016002152A (es) 2013-08-21 2017-01-05 Curevac Ag Metodo para aumentar la expresion de proteinas codificadas por arn.
WO2015024669A1 (en) 2013-08-21 2015-02-26 Curevac Gmbh Combination vaccine
AU2014310932B2 (en) 2013-08-21 2019-06-06 CureVac SE Composition and vaccine for treating lung cancer
ES2747762T3 (es) 2013-08-21 2020-03-11 Curevac Ag Vacuna contra el virus respiratorio sincitial (RSV)
WO2015024665A1 (en) 2013-08-21 2015-02-26 Curevac Gmbh Rabies vaccine
KR20160043103A (ko) 2013-08-21 2016-04-20 큐어백 아게 전립선암 치료를 위한 조성물 및 백신
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. 低密度リポタンパク質受容体をコードするポリヌクレオチド
AU2014337156A1 (en) 2013-10-18 2016-05-12 Modernatx, Inc. Compositions and methods for tolerizing cellular systems
CN105658800A (zh) 2013-10-22 2016-06-08 夏尔人类遗传性治疗公司 Mrna的cns递送及其用途
EP3574923A1 (en) 2013-10-22 2019-12-04 Translate Bio, Inc. Mrna therapy for phenylketonuria
ES2806575T3 (es) 2013-11-01 2021-02-18 Curevac Ag ARN modificado con propiedades inmunoestimuladoras disminuidas
WO2015082080A1 (en) * 2013-12-05 2015-06-11 Silence Therapeutics Gmbh Means for lung specific delivery
US20160367638A1 (en) 2013-12-19 2016-12-22 Crystal BYERS LEPTIN mRNA COMPOSITIONS AND FORMULATIONS
EP4019506A1 (en) 2013-12-19 2022-06-29 Novartis AG Lipids and lipid compositions for the delivery of active agents
US10059655B2 (en) * 2013-12-19 2018-08-28 Novartis Ag Lipids and lipid compositions for the delivery of active agents
JP6704850B2 (ja) 2013-12-30 2020-06-03 キュアバック アーゲー 人工核酸分子
JP6584414B2 (ja) 2013-12-30 2019-10-02 キュアバック アーゲー 人工核酸分子
SG10201805660WA (en) 2013-12-30 2018-08-30 Curevac Ag Methods for rna analysis
EP3791863B1 (en) 2014-01-21 2025-09-10 Anjarium Biosciences AG Process for the production of hybridosomes
US10821175B2 (en) 2014-02-25 2020-11-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
WO2015134332A2 (en) 2014-03-01 2015-09-11 Nasar, Farooq Recombinant isfahan viral vectors
ES2754239T3 (es) 2014-03-12 2020-04-16 Curevac Ag Combinación de vacunación y agonistas de OX40
RS66380B1 (sr) 2014-04-23 2025-02-28 Modernatx Inc Vakcine nukleinske kiseline
US10286086B2 (en) 2014-06-19 2019-05-14 Modernatx, Inc. Alternative nucleic acid molecules and uses thereof
IL298516B2 (en) 2014-06-25 2025-03-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle compositions for nucleic acid delivery
US20170204152A1 (en) 2014-07-16 2017-07-20 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3169783A4 (en) 2014-07-17 2018-10-03 Modernatx, Inc. Terminal modifications of polynucleotides
ES2969956T3 (es) 2014-09-05 2024-05-23 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
CN104644555A (zh) 2014-11-18 2015-05-27 中国科学院过程工程研究所 一种避免加速血液清除现象的长循环脂质体、制备方法及应用
EP3247363A4 (en) 2015-01-21 2018-10-03 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
WO2016123864A1 (en) 2015-02-08 2016-08-11 Tongli Biomedical Co., Ltd. Lipid nanoparticles and uses thereof
WO2016164762A1 (en) 2015-04-08 2016-10-13 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
EP3283059B1 (en) 2015-04-13 2024-01-03 CureVac Manufacturing GmbH Method for producing rna compositions
WO2016201377A1 (en) 2015-06-10 2016-12-15 Moderna Therapeutics, Inc. Targeted adaptive vaccines
CA2990202A1 (en) 2015-06-29 2017-01-05 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017011773A2 (en) 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
EP4218805A1 (en) 2015-07-21 2023-08-02 ModernaTX, Inc. Infectious disease vaccines
WO2017015457A1 (en) 2015-07-21 2017-01-26 Modernatx, Inc. Ebola vaccine
WO2017019935A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Multimeric mrna
WO2017020026A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
US20180237849A1 (en) 2015-08-17 2018-08-23 Modernatx, Inc. Rna mapping/fingerprinting
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
KR20180037053A (ko) 2015-08-21 2018-04-10 화이자 인코포레이티드 치료제를 포함하는 치료 나노입자 및 그의 제조 및 사용 방법
ES2910425T3 (es) 2015-09-17 2022-05-12 Modernatx Inc Compuestos y composiciones para la administración intracelular de agentes terapéuticos
ES2810701T5 (es) 2015-10-05 2024-07-11 Modernatx Inc Procedimientos para la administración terapéutica de medicamentos de ácido ribonucleico mensajero
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
US20180318409A1 (en) 2015-10-22 2018-11-08 Modernatx, Inc. Cancer vaccines
CN118846026A (zh) 2015-10-22 2024-10-29 摩登纳特斯有限公司 广谱流感病毒疫苗
AU2016342049B2 (en) 2015-10-22 2023-05-18 Modernatx, Inc. Herpes simplex virus vaccine
JP7687767B2 (ja) 2015-10-22 2025-06-03 モデルナティエックス インコーポレイテッド 呼吸器合胞体ウイルスワクチン
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
EP4349405A3 (en) 2015-10-22 2024-06-19 ModernaTX, Inc. Respiratory virus vaccines
TN2018000152A1 (en) 2015-10-22 2019-10-04 Modernatx Inc Nucleic acid vaccines for varicella zoster virus (vzv)
EP3364982A4 (en) 2015-10-22 2019-04-17 ModernaTX, Inc. VACCINES AGAINST SEXUALLY TRANSMITTED DISEASES
JP6921833B2 (ja) 2015-10-22 2021-08-18 モデルナティーエックス, インコーポレイテッド ヒトサイトメガロウイルスワクチン
WO2017075038A1 (en) 2015-10-26 2017-05-04 Rana Therapeutics, Inc. Nanoparticle formulations for delivery of nucleic acid complexes
WO2018081480A1 (en) 2016-10-26 2018-05-03 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
WO2017099823A1 (en) 2015-12-10 2017-06-15 Modernatx, Inc. Compositions and methods for delivery of therapeutic agents
CA3007108A1 (en) 2015-12-17 2017-06-22 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
EP4036079B1 (en) 2015-12-22 2025-11-19 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
US20210206818A1 (en) 2016-01-22 2021-07-08 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
SG11201810162PA (en) 2016-05-18 2018-12-28 Modernatx Inc Polynucleotides encoding citrin for the treatment of citrullinemia type 2
JP2019519601A (ja) 2016-05-18 2019-07-11 モダーナティエックス・インコーポレイテッドModernaTX, Inc. 急性間欠性ポルフィリン症の治療のためのポルホビリノゲン脱アミノ酵素をコードするポリヌクレオチド
WO2017201332A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding acyl-coa dehydrogenase, very long-chain for the treatment of very long-chain acyl-coa dehydrogenase deficiency
WO2017201342A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
AU2017268394A1 (en) 2016-05-18 2019-01-03 Modernatx, Inc. Polynucleotides encoding relaxin
JP2019519516A (ja) 2016-05-18 2019-07-11 モデルナティーエックス, インコーポレイテッド がんの治療のためのmRNA併用療法
WO2017201333A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding lipoprotein lipase for the treatment of hyperlipidemia
US11801227B2 (en) 2016-05-18 2023-10-31 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
MA45041A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour la galactose-1-phosphate uridylyltransférase destinés au traitement de la galactosémie de type 1
US20190382774A1 (en) 2016-05-18 2019-12-19 Modernatx, Inc. Polyribonucleotides containing reduced uracil content and uses thereof
CA3024507A1 (en) * 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding .alpha.-galactosidase a for the treatment of fabry disease
EP3468537A1 (en) 2016-06-14 2019-04-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
WO2017219033A1 (en) 2016-06-17 2017-12-21 Montana State University Bidirectional targeting for genome editing
CA3034681A1 (en) 2016-06-30 2018-01-04 Arbutus Biopharma Corporation Compositions and methods for delivering messenger rna
WO2018039131A1 (en) * 2016-08-22 2018-03-01 Protiva Biotherapeutics, Inc. Anti-pd-1 antibodies, or fragments thereof, for treating hepatitis b
CA3036831A1 (en) 2016-09-14 2018-03-22 Modernatx, Inc. High purity rna compositions and methods for preparation thereof
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
AU2017347837A1 (en) 2016-10-26 2019-06-06 Modernatx, Inc. Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
EP3532613A4 (en) 2016-10-26 2020-05-06 ModernaTX, Inc. METHOD AND COMPOSITIONS FOR RNA MAPPING
US20200163878A1 (en) 2016-10-26 2020-05-28 Curevac Ag Lipid nanoparticle mrna vaccines
EP3538067A1 (en) 2016-11-08 2019-09-18 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
AU2017357758B2 (en) 2016-11-10 2023-11-16 Translate Bio, Inc. Improved process of preparing mRNA-loaded lipid nanoparticles
WO2018089790A1 (en) 2016-11-10 2018-05-17 Translate Bio, Inc. Improved ice-based lipid nanoparticle formulation for delivery of mrna
EP3538146A4 (en) 2016-11-11 2020-07-15 ModernaTX, Inc. INFLUENZA VACCINE
US11103578B2 (en) 2016-12-08 2021-08-31 Modernatx, Inc. Respiratory virus nucleic acid vaccines
US11384352B2 (en) 2016-12-13 2022-07-12 Modernatx, Inc. RNA affinity purification
EP3558355A2 (en) 2016-12-23 2019-10-30 CureVac AG Henipavirus vaccine
US20180243225A1 (en) 2017-01-25 2018-08-30 Modernatx, Inc. Ebola/marburg vaccines
WO2018144778A1 (en) 2017-02-01 2018-08-09 Modernatx, Inc. Polynucleotide secondary structure
AU2018214556A1 (en) 2017-02-01 2019-08-15 Modernatx, Inc. Immunomodulatory therapeutic mRNA compositions encoding activating oncogene mutation peptides
SG11201906895WA (en) 2017-02-01 2019-08-27 Modernatx Inc Rna cancer vaccines
EP3582790A4 (en) 2017-02-16 2020-11-25 ModernaTX, Inc. VERY POWERFUL IMMUNOGENIC COMPOSITIONS
WO2018157009A1 (en) 2017-02-24 2018-08-30 Modernatx, Inc. Nucleic acid-based therapy of muscular dystrophies
US11464848B2 (en) 2017-03-15 2022-10-11 Modernatx, Inc. Respiratory syncytial virus vaccine
WO2018170336A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
RS63953B1 (sr) 2017-03-15 2023-02-28 Modernatx Inc Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava
MA47790A (fr) 2017-03-17 2021-05-05 Modernatx Inc Vaccins à base d'arn contre des maladies zoonotiques
US20200038499A1 (en) 2017-03-22 2020-02-06 Modernatx, Inc. Rna bacterial vaccines
EP3607074A4 (en) 2017-04-05 2021-07-07 Modernatx, Inc. REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
MA49463A (fr) 2017-04-26 2021-05-05 Modernatx Inc Vaccin contre le virus de l'herpès simplex
WO2018232120A1 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. RNA FORMULATIONS
WO2018232355A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna antibodies
CN111372580A (zh) 2017-07-24 2020-07-03 国邑药品科技股份有限公司 包含弱酸药物的脂质体组合物及其用途
EP3668979A4 (en) 2017-08-18 2021-06-02 Modernatx, Inc. METHOD OF HPLC ANALYSIS
EP3668971B8 (en) 2017-08-18 2024-05-29 ModernaTX, Inc. Rna polymerase variants
US20200254086A1 (en) 2017-08-18 2020-08-13 Moderna TX, Inc. Efficacious mrna vaccines
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. HPLC ANALYTICAL PROCESSES
CA3073211A1 (en) * 2017-08-31 2019-03-07 Modernatx, Inc. Methods of making lipid nanoparticles
WO2019055807A1 (en) 2017-09-14 2019-03-21 Modernatx, Inc. RNA VACCINES AGAINST ZIKA VIRUS
EA202090919A1 (ru) 2017-10-31 2020-09-09 Модернатикс, Инк. Липидные наночастицы для доставки модифицированной рнк, кодирующей полипептид vegf-a
US20190192646A1 (en) 2017-11-03 2019-06-27 Modernatx, Inc. Salmonella vaccines
CA3083102A1 (en) 2017-11-21 2019-05-31 Modernatx, Inc. Epstein-barr virus vaccines
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
DE202019006108U1 (de) 2018-04-17 2024-12-16 CureVac SE Neue RSV-RNA-Moleküle und Zusammensetzungen für die Impfung
CN112437767B (zh) 2018-05-24 2023-10-27 川斯勒佰尔公司 硫酯阳离子脂质
SG11202012770RA (en) 2018-06-27 2021-01-28 Modernatx Inc Personalized cancer vaccine epitope selection
CN112543629A (zh) 2018-06-28 2021-03-23 阿斯利康(瑞典)有限公司 外泌体胞外囊泡及其使用方法
CN112839639A (zh) 2018-08-29 2021-05-25 川斯勒佰尔公司 制备负载mRNA的脂质纳米颗粒的改进方法
CA3111836A1 (en) 2018-09-13 2020-03-19 Modernatx, Inc. Modified mrna for the treatment of progressive familial intrahepatic cholestasis disorders
CN112996854B (zh) 2018-09-19 2024-08-30 摩登纳特斯有限公司 高纯度peg脂质和其用途
EP3852732A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Peg lipids and uses thereof
EP3853202A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
WO2020077007A1 (en) 2018-10-09 2020-04-16 The University Of British Columbia Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto
WO2020081933A1 (en) 2018-10-19 2020-04-23 Translate Bio, Inc. Pumpless encapsulation of messenger rna
JP2022506839A (ja) 2018-11-07 2022-01-17 モデルナティエックス インコーポレイテッド Rnaがんワクチン
CN113939282A (zh) 2019-01-31 2022-01-14 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
MA55037A (fr) 2019-02-20 2021-12-29 Modernatx Inc Variants d'arn polymérase pour le coiffage co-transcriptionnel
KR20210149727A (ko) 2019-03-11 2021-12-09 모더나티엑스, 인크. 유가식(fed-batch) 시험관내 전사 공정
WO2020190750A1 (en) 2019-03-15 2020-09-24 Modernatx, Inc. Hiv rna vaccines
SG11202112574RA (en) 2019-05-14 2021-12-30 Translate Bio Inc Improved process of preparing mrna-loaded lipid nanoparticles
WO2020243561A1 (en) 2019-05-31 2020-12-03 Modernatx, Inc. Expanded t cell assay
AU2020311364B2 (en) 2019-07-08 2025-12-18 Translate Bio, Inc. Improved mRNA-loaded lipid nanoparticles and processes of making the same
MX2022000934A (es) 2019-07-23 2022-02-14 Translate Bio Inc Composiciones estables de nanoparticulas lipidicas cargadas de arnm y procesos de fabricacion.
BR112022002548A2 (pt) 2019-08-14 2022-06-14 Modernatx Inc Processos para purificar produtos a jusante de transcrição in vitro
EP4028030A4 (en) 2019-09-11 2023-09-27 ModernaTX, Inc. VACCINE AGAINST HUMAN CYTOMEGALOVIRUS
US20220349006A1 (en) 2019-09-19 2022-11-03 Moderna TX, Inc. Cap guides and methods of use thereof for rna mapping
AR120080A1 (es) 2019-09-19 2022-02-02 Modernatx Inc Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos
JP2023508881A (ja) 2019-12-20 2023-03-06 トランスレイト バイオ, インコーポレイテッド Mrna担持脂質ナノ粒子を調製する改善されたプロセス
US20210217484A1 (en) 2020-01-10 2021-07-15 Modernatx, Inc. Variational autoencoder for biological sequence generation
US20210228707A1 (en) 2020-01-28 2021-07-29 Modernatx, Inc. Coronavirus rna vaccines
CN115103682A (zh) 2020-01-30 2022-09-23 摩登纳特斯有限公司 呼吸道病毒免疫组合物
MX2022009410A (es) 2020-01-31 2022-10-18 Modernatx Inc Metodos de preparacion de nanoparticulas lipidicas.
EP4100052A2 (en) 2020-02-07 2022-12-14 ModernaTX, Inc. Sars-cov-2 mrna domain vaccines
US11969480B2 (en) 2020-02-25 2024-04-30 Translate Bio, Inc. Processes of preparing mRNA-loaded lipid nanoparticles
CA3178455A1 (en) 2020-04-09 2021-10-14 Suzhou Abogen Biosciences Co., Ltd. Lipid nanoparticle composition
WO2021211343A1 (en) 2020-04-13 2021-10-21 Modernatx, Inc. Zika virus mrna vaccines
WO2021222304A1 (en) 2020-04-27 2021-11-04 Modernatx, Inc. Sars-cov-2 rna vaccines
EP4149484A4 (en) 2020-05-15 2024-10-02 ModernaTX, Inc. RNA FORMULATIONS FOR HIGH VOLUME DELIVERY
AU2021273502A1 (en) 2020-05-15 2023-02-02 Translate Bio, Inc. Lipid nanoparticle formulations for mRNA delivery
WO2021159130A2 (en) 2020-05-15 2021-08-12 Modernatx, Inc. Coronavirus rna vaccines and methods of use
US20230190761A1 (en) 2020-05-21 2023-06-22 Modernatx, Inc. Methylene blue stabilized mrna compositions
US20230287437A1 (en) 2020-06-05 2023-09-14 Modernatx, Inc. Bacterial strains for dna production
US20230277457A1 (en) 2020-08-06 2023-09-07 Modernatx, Inc. Methods of preparing lipid nanoparticles
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
US20230355743A1 (en) 2020-09-25 2023-11-09 Modernatx, Inc. Multi-proline-substituted coronavirus spike protein vaccines
US20220133631A1 (en) 2020-10-12 2022-05-05 Translate Bio, Inc. Process of preparing ice-based lipid nanoparticles
CN116490166A (zh) 2020-10-12 2023-07-25 翻译生物公司 制备加载mRNA的脂质纳米颗粒的改进方法
US12329811B2 (en) 2021-01-11 2025-06-17 Modernatx, Inc. Seasonal RNA influenza virus vaccines
AU2022208057A1 (en) 2021-01-15 2023-08-03 Modernatx, Inc. Variant strain-based coronavirus vaccines
EP4277653A1 (en) 2021-01-15 2023-11-22 ModernaTX, Inc. Variant strain-based coronavirus vaccines
US20240100145A1 (en) 2021-03-05 2024-03-28 Moderna TX, Inc. Vlp enteroviral vaccines
EP4313072A1 (en) 2021-03-26 2024-02-07 ModernaTX, Inc. Pertussis vaccine
WO2022212442A1 (en) 2021-03-31 2022-10-06 Modernatx, Inc. Synthesis of trinucleotide and tetranucleotide caps for mrna production
EP4314046A4 (en) 2021-04-01 2025-03-19 ModernaTX, Inc. Mucosal expression of antibody structures and isotypes by mRNA
JP2024512780A (ja) 2021-04-01 2024-03-19 モデルナティエックス インコーポレイテッド 多価rna組成物中のrna種の識別及び比率決定のための方法
EP4322993A1 (en) 2021-04-13 2024-02-21 ModernaTX, Inc. Respiratory virus combination vaccines
WO2022221336A1 (en) 2021-04-13 2022-10-20 Modernatx, Inc. Respiratory syncytial virus mrna vaccines
CA3216490A1 (en) 2021-04-13 2022-10-20 Modernatx, Inc. Epstein-barr virus mrna vaccines
EP4322994A1 (en) 2021-04-14 2024-02-21 ModernaTX, Inc. Influenza-coronavirus combination vaccines
WO2022232585A1 (en) 2021-04-29 2022-11-03 Modernatx, Inc. Lyophilization methods for preparing lipid formulated therapeutics
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
EP4355761A1 (en) 2021-06-14 2024-04-24 ModernaTX, Inc. Mrna vaccines encoding flexible coronavirus spike proteins
WO2022266012A1 (en) 2021-06-14 2022-12-22 Modernatx, Inc. Coronavirus glycosylation variant vaccines
WO2022266389A1 (en) 2021-06-17 2022-12-22 Modernatx, Inc. Alternative rna purification strategies
EP4366768A4 (en) 2021-07-09 2025-05-21 ModernaTX, Inc. Pan-human coronavirus vaccines
WO2023283642A2 (en) 2021-07-09 2023-01-12 Modernatx, Inc. Pan-human coronavirus concatemeric vaccines
WO2023283645A1 (en) 2021-07-09 2023-01-12 Modernatx, Inc. Pan-human coronavirus domain vaccines
CN118019527A (zh) 2021-07-26 2024-05-10 摩登纳特斯有限公司 用于制备脂质纳米颗粒组合物的方法
CN118019526A (zh) 2021-07-26 2024-05-10 摩登纳特斯有限公司 用于制备将有效负载分子递送至气道上皮的脂质纳米颗粒组合物的方法

Also Published As

Publication number Publication date
JP7275111B2 (ja) 2023-05-17
CN111315359A (zh) 2020-06-19
US20240009131A1 (en) 2024-01-11
AU2018326799A1 (en) 2020-02-27
US20200306191A1 (en) 2020-10-01
JP2023093756A (ja) 2023-07-04
CA3073211A1 (en) 2019-03-07
EP3675817A1 (en) 2020-07-08
WO2019046809A1 (en) 2019-03-07
JP2020532528A (ja) 2020-11-12
US11744801B2 (en) 2023-09-05
JP2025108727A (ja) 2025-07-23
US12357575B2 (en) 2025-07-15

Similar Documents

Publication Publication Date Title
MX2020002348A (es) Métodos de elaboración de nanopartículas lipídicas.
WO2017049245A3 (en) Compounds and compositions for intracellular delivery of therapeutic agents
MX2018010529A (es) Composiciones y metodos para la produccion y administracion de acido ribonucleico.
MX2020006065A (es) Metodos y productos para la produccion y administracion de acido nucleico.
MX2022007680A (es) Nanoparticulas lipidicas para administracion de acidos nucleicos.
EP4328314A3 (en) Lipid nanoparticle methods and compositions for producing engineered erythroid cells
WO2017075389A8 (en) Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
MX2018011384A (es) Arn de replicacion en trans.
EP4434997A3 (en) Delivery of negatively charged proteins using cationic lipids
PH12018500965A1 (en) Methods and compositions for gene editing in hematopoietic stem cells
MY200633A (en) Methods and compositions for nucleoside triphosphate and ribonucleic acid production
MY195729A (en) Cell-Free Production of Ribonucleic Acid
EP4614148A3 (en) Synergistic enhancement of the delivery of nucleic acids via blended formulations
BR112015022192A2 (pt) composições eletrodepositadas e ligas nanolaminadas para os artigos preparados por meio dos processos de fabricação aditiva
MX2018001617A (es) Composiciones de crispr-cas9 diseñados y metodos de uso.
EP4292600A3 (en) Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
MX376623B (es) Cultivo celular metabolicamente optimizado.
MA39867A (fr) Procédés d'isolement, de culture et de manipulation génétique de populations de cellules immunitaires pour une thérapie adoptive
BR112018010635A2 (pt) linhagens celulares estáveis para a produção retroviral
WO2019002512A3 (en) GLYCOPROTEINS CUSTOMIZED FROM ENGINEERING AND FULLY FUNCTIONAL
WO2017210666A3 (en) Functionalized nanoparticles for the intracellular delivery of biologically active molecules and methods for their manufacture and use
PH12014502870A1 (en) Method of producing recombinant iduronate-2-sulfatase
MX2016013223A (es) Formulacion en polvo de medio de compuesto y metodo de preparacion de medio liquido para cultivo celular.
EP4276187A3 (en) Methods and compositions for enhancing functional myelin production
IL246525B (en) Pomegranate derived cell culture and methods for preparing and using the same